Finzati - Logo
CRLBF logo

Cresco Labs Inc.

CRLBF • Drug Manufacturers - Specialty & Generic
$0.78
▲ +0.04 (+5.23%)
Current price
EarningsLatest report: Mar 31, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$284.10M
Growth
—
Cash Flow
3/5
Trend
Mostly stable
Evidence
Positive free cash flow · 0.11Healthy liquidity · 2.59Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 8, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.78
Change5.23%
Shares Out364.23M
Market Cap$284.10M
Enterprise Value$663.80M
52W Range0.43 - 2.30
Beta1.71
P/E-2.08
P/S0.44
P/B0.84
P/FCF-88.23
EV/Sales1.03

Investment DNA

How strong this company looks for long-term investors

56
out of 100
Business Quality
Margins, moat, returns
33/100
Financial Strength
Debt, cash, stability
61/100
Growth Potential
Revenue and expansion
58/100
Price Attractiveness
Cheap or expensive today
92/100
Why this score▼
Positive free cash flow · 0.11Healthy liquidity · 2.59Weak profitability

Analyst view

Analyst sentiment and price target

CRLBF
Analyst sentiment
Based on 7 analyst votes · 2026-09-05
79/100
Bullish
Bullish
4
Hold
3
Bearish
0
Price Target
2026-06-06
Low
$2.50
Mean
$5.50
Median
$5.50
High
$8.50

Company Overview

IPO: 12/3/2018
Industry: Drug Manufacturers - Specialty & Generic
P/B i: 0.84
Debt / Equity i: 1.72
Operating Margin: 11.76%
Net Margin: -21.35%
ROE i: -
ROIC: -

Financial Health

Score12 / 20
Debt / Equity: 1.72
Current Ratio: 2.59
Quick Ratio: 2.59
Status: Good
🧾

No insider activity

No recent insider transactions available.